person · Reporting owner
Greenman William Mariner
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director · President and CEO | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,053,036 |
Ending reported balance
After 2026-06-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-30 · Grant · Disposed 192,500 · Balance 5,154,955 Row 2 · 2026-06-30 · Sale · Disposed 101,919 · Balance 5,053,036 F1: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person. F2: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.
F2: Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.84 to $3.03 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 23,643 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2024-09-14 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 3,600 · Balance 0 F2: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of September 15, 2014, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.00 · Expires 2025-04-13 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 8,000 · Balance 0 F3: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of March 30, 2015, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.10 · Expires 2026-06-08 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F4: This stock option award, which provided for ratable vesting in 4 quarterly installments band vested in full on the one year anniversary of June 9, 2016, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.75 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 2,600 · Balance 0 F5: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 8, 2017, was canceled for no consideration upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.00 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 4,000 · Balance 0 F6: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 6, 2018, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2029-05-13 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 6,000 · Balance 0 F7: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 14, 2019, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2030-05-04 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-11 · Disposition to issuer · Disposed 6,000 · Balance 0 F8: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 5, 2020, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F9: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of September 15, 2014, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F3: This stock option award, which provided for ratable vesting in 12 monthly installments and vested in full on the one year anniversary of March 30, 2015, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F4: This stock option award, which provided for ratable vesting in 4 quarterly installments band vested in full on the one year anniversary of June 9, 2016, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F5: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 8, 2017, was canceled for no consideration upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of June 6, 2018, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F7: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 14, 2019, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F8: This stock option award, which provided for ratable vesting in 4 quarterly installments and vested in full on the one year anniversary of May 5, 2020, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F9: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F10: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 104,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 12, 2022 Filed Mar 16, 2022 02:00 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 151,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-019066 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 435,000 | Not disclosed Strike: $5.76 | Not disclosed |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · derivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,000 Underlying: Common Stock · 435,000 shares Expires 2032-02-28 F7 · price: Not applicable. F8 · derivative.exercise_date: One forth (1/4) of the shares subject to the Option shall vest on the first anniversary of the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vest monthly thereafter. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | GrantCommon Stock | 217,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · nonDerivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,811,518 F5 · shares: Represents the number of shares underlying RSUs. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vests in three equal annual installments beginning on March 12, 2023, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 380,000 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · derivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 380,000 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: One eighth (1/8) of the shares subject to the Option shall vest six (6) months after the transaction date and one forty-eighth (1/48th) of the shares subject to the Option shall vest monthly thereafter. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 93,000 | $5.73 | $532,648.20 |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594,018 F2 · shares: Represents shares sold to cover the exercise price, the statutory tax withholding obligations and corresponding brokerage fee in connection with the exercise of the option listed in Table II prior to expiration. F4 · price: The reported price in column 4 is a weighted average price ranging from $5.665 to $5.79 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 215,263 | $5.69 | $1,224,394.42 |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,687,018 F2 · shares: Represents shares sold to cover the exercise price, the statutory tax withholding obligations and corresponding brokerage fee in connection with the exercise of the option listed in Table II prior to expiration. F3 · price: The reported price in column 4 is a weighted average price ranging from $5.56 to $5.77 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| February 25, 2022 Filed Mar 2, 2022 02:18 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 380,000 | $3.75 | $1,425,000.00 |
DisclosureSEC source: 0001209191-22-014447 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,902,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,445 and 2,164 shares purchased under Issuer's Employee Stock Purchase Plan on 08/31/21 and 02/28/22. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 18:47 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,663 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001209191-21-061428 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,663 shares Expires 2021-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 18:47 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | Exercise / conversionCommon Stock | 1,663 | $2.60 | $4,323.80 |
DisclosureSEC source: 0001209191-21-061428 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:12 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $2.08 | Not disclosed |
DisclosureSEC source: 0001209191-21-049989 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: One eighth (1/8th) of the shares subject to the Option vested six (6) months after the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vested on the first day of each month thereafter. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:12 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 100,000 | $2.08 | $208,000.00 |
DisclosureSEC source: 0001209191-21-049989 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,518,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 21:34 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 5,948 | $0.00 Strike: $16.81 | $0.00 |
DisclosureSEC source: 0001209191-21-038795 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,948 Underlying: Common Stock · 5,948 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 4, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 01:15 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 550,000 | Not disclosed Strike: $2.70 | Not disclosed |
DisclosureSEC source: 0001209191-21-027700 · doc4.xml · derivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 550,000 shares Expires 2021-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: One eighth (1/8th) of the shares subject to the Option vested six (6) months after the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vested on the first day of each month thereafter. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 01:15 UTC | CERUS CORP CERS · Entity 5431 | Tax withholdingCommon Stock | 233,859 | $6.35 | $1,485,004.65 |
DisclosureSEC source: 0001209191-21-027700 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,418,672 F1 · shares: Represents a net exercise of outstanding stock options. These shares were withheld by Issuers for payment of the exercise price, based on the market price of Issuers common stock on April 15, 2021 of $6.35 in accordance with the terms of the Issuers Amended and Restated 2008 Equity Incentive Plan. The Reporting Person elected to pay the withholding taxes in cash. Read SEC document |
| April 16, 2021 Filed Apr 21, 2021 01:15 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 550,000 | $2.70 | $1,485,000.00 |
DisclosureSEC source: 0001209191-21-027700 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,652,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 52,484 | $6.38 | $334,727.21 |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,102,531 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. F4 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.285 to $6.445 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 76,272 | $6.38 | $486,439.93 |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,652 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. F4 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.285 to $6.445 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 27,651 | $6.38 | $176,349.78 |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,257 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. F4 · price: The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.285 to $6.445 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 104,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · derivative · entry 9 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,887 Underlying: Common Stock · 104,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F6 · price: Not applicable. F8 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2021. F8 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 151,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · derivative · entry 8 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,666 Underlying: Common Stock · 151,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F6 · price: Not applicable. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. F7 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 71,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · derivative · entry 7 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F6 · price: Not applicable. F5 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2019. F5 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2019. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 104,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 151,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,126,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 23:37 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 71,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021140 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · balance_after: Includes 2,341 and 3,052 shares purchased under Issuer's Employee Stock Purchase Plan on 08/31/20 and 02/28/21, respectively. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:08 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 194,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017459 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,000 Underlying: Common Stock · 194,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. F4 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:08 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 380,000 | Not disclosed Strike: $6.52 | Not disclosed |
DisclosureSEC source: 0001209191-21-017459 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 380,000 shares Expires 2031-02-28 F2 · price: Not applicable. F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the Option shall vest on the first anniversary of the date of grant, and one forty-eighth (1/48th) of the shares subject to the Option vest monthly thereafter. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 20:44 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 23,522 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-20-054241 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,522 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on November 6, 2020 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 00:23 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionOption (Right to Buy) · Derivative | 100,000 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001209191-20-048464 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2020-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: One eighth (1/8th) of the shares subject to the Option vested six (6) months after the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vested on the first day of each month thereafter. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 00:23 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 100,000 | $3.00 | $300,000.00 |
DisclosureSEC source: 0001209191-20-048464 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 28, 2020 19:57 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011287 · doc1.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of May 5, 2020, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,458 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001567619-20-006852 · doc1.xml · derivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,458 shares Expires 2020-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. F2 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,566 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001567619-20-006852 · doc1.xml · derivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,566 shares Expires 2020-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. F2 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,811 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001567619-20-006852 · doc1.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,811 shares Expires 2020-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. F2 · derivative.exercise_date: The shares subject to the Option are fully vested and immediately exercisable. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 17:18 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | Exercise / conversionCommon Stock | 19,835 | $0.45 | $8,925.75 |
DisclosureSEC source: 0001567619-20-006852 · doc1.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction by the Reporting Person is an exercise of an in-the-money option for cash consideration and does not involve the sale of any shares. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 69,210 | $3.59 | $248,789.19 |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 6 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,849 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 151,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 5 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 27,865 | $3.59 | $100,166.32 |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 4 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,392 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 71,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 3 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | SaleCommon Stock | 10,936 | $3.59 | $39,311.64 |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 699,590 F3 · shares: Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person. Read SEC document |
| March 17, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 28,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · balance_after: Includes 1,445 and 2,471 shares purchased under Issuer's Employee Stock Purchase Plan on 08/30/19 and 02/28/20, respectively. Read SEC document |
| March 12, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 151,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · derivative · entry 9 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,333 Underlying: Common Stock · 151,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F7 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. F7 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. Read SEC document |
| March 12, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 71,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · derivative · entry 8 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,666 Underlying: Common Stock · 71,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F6 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2019. F6 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2019. Read SEC document |
| March 12, 2020 Filed Mar 25, 2020 01:19 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-021047 · doc4.xml · derivative · entry 7 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F5 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2018. F4 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2018. Read SEC document |
| March 02, 2020 Filed Mar 16, 2021 23:05 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 316,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-021107 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,250 Underlying: Common Stock · 316,250 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F2 · price: Not applicable. F4 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2021. F4 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2021. Read SEC document |
| March 02, 2020 Filed Mar 16, 2021 23:05 UTC | CERUS CORP CERS · Entity 5431 | GrantOption (Right to Buy) · Derivative | 632,500 | Not disclosed Strike: $5.11 | Not disclosed |
DisclosureSEC source: 0001209191-21-021107 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632,500 Underlying: Common Stock · 632,500 shares Expires 2030-03-01 F2 · price: Not applicable. F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the Option shall vest on the first anniversary of the date of grant, and one forty-eighth (1/48th) of the shares subject to the Option vest monthly thereafter. Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:42 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $2.15 Strike: $2.15 | $86,000.00 |
DisclosureSEC source: 0001209191-19-050602 · doc4.xml · derivative · entry 2 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2019-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| September 24, 2019 Filed Sep 25, 2019 00:42 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 40,000 | $2.15 | $86,000.00 |
DisclosureSEC source: 0001209191-19-050602 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:23 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 455,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-035794 · doc4.xml · derivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,000 Underlying: Common Stock · 455,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. F2 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on March 12, 2020. Read SEC document |
| June 04, 2019 Filed Jun 4, 2019 21:09 UTC | CERUS CORP CERS · Entity 5431 | PurchaseCommon Stock | 10,000 | $4.60 | $46,000.00 |
DisclosureSEC source: 0001209191-19-034398 · doc4.xml · nonDerivative · entry 1 Greenman William Mariner · CIK 0001377258 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,485 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.